Uterine fibroids
Conditions
Interventions
Control group:An equal amount of saline was pumped intravenously from ten minutes before induction of anesthesia to thirty minutes before the end of surgery.
Subdose esketamine group (S1):Intravenous pumping of 0.25 mg/kg/h esketamine was administered ten minutes before induction of anesthesia to thirty minutes before the end of surgery.
esketamine group (S2):Intravenous pumping of 0.5 mg/kg/h esketamine was administered ten minutes before induction of anesthesia to thirty minutes before the end of surgery.
Sponsors
Second Hospital of Lanzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Patients undergoing laparoscopic myomectomy or total hysterectomy in gynecology department of our hospital; (2) ASA classification I-II; (3) Patient age 18-60 years; (4) BMI 18-30 kg/m2; (5) No allergic reaction to the test drug, and no recent history of analgesic intake or drug abuse; (6)Patients with no previous constipation, diarrhea, or other digestive disorders, and patients with no history of gastrointestinal surgery.
Exclusion criteria
Exclusion criteria: (1) Those with severe heart disease, hepatic insufficiency (Child-Pugh classification C) or renal insufficiency (blood creatinine > 442 µmol/L or those who need renal replacement therapy), ASA classification = III, or morbid obesity (BMI > 30 kg/m2); (2) Those with neurological or psychiatric disorders who are unable to cooperate; (3) Those who refuse to participate in this study; (4) Contraindications associated with esketamine: allergy to esketamine; patients at serious risk for cranial or intracranial elevation of blood pressure; patients with poorly controlled or untreated hypertension (resting systolic/diastolic blood pressure greater than 180/100 mmHg); pre-eclampsia and eclampsia; patients with untreated or under-treated hyperthyroidism (hyperthyroid); patients with psychotic disorders, major depressive disorder, schizophrenia or dementia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| I-FABP;claudin-1;I-FEED scores;First bowel movement time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient General Information;Total use of propofol, remifentanil, sufentanil;Length of surgery, length of pneumoperitoneum, length of hospital stay;Patient's vital signs fluctuate; | — |
Countries
China
Contacts
Public ContactYing-bin Wang
Second Hospital of Lanzhou University
Outcome results
None listed